<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372786</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2014-517_OPTICA</org_study_id>
    <nct_id>NCT02372786</nct_id>
  </id_info>
  <brief_title>7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream</brief_title>
  <acronym>OPTICA</acronym>
  <official_title>A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of 7% lidocaine / 7% tetracaine cream
      and 2,5% lidocaine / 2,5% prilocaine cream in reducing self-reported pain during a single
      laser procedure in the treatment of acne keloidalis nuchae and tattoo removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will compare the efficacy of 7% lidocaine / 7% tetracaine cream and 2,5%
      lidocaine / 2,5% prilocaine cream in reducing self-reported pain during a single laser
      procedure in the treatment of acne keloidalis nuchae and tattoo removal. Patients will be
      asked to fill in questionnaires to:

        -  assess the severity of pain experienced (VAS score) during laser treatment,

        -  evaluate whether the pain relief is adequate and,

        -  evaluate the amount of money patients would be willing to pay for the cream that
           provided the 'best' pain relief.

      One week after the visit the patient will have a telephone consultation. The patients will
      be asked if they experienced any symptoms, which will be recorded as adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Self-reported pain (10 point visual analog scale).</measure>
    <time_frame>5 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>adequate pain relief (yes/no);</measure>
    <time_frame>10 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>willing to spend around 25 euro for best pain relief (yes/no).</measure>
    <time_frame>Same day as treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor the nature and frequency of adverse events</measure>
    <time_frame>one week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tattoo</condition>
  <condition>Acne Keloidalis Nuchae</condition>
  <arm_group>
    <arm_group_label>2,5% lidocaine / 2,5% prilocaine cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients recieve both the active comparator and the experimental arm. Patients in the acne keloidalis nuchae group will be treated with the Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser and patients in the tattoo removal group with the Q-switched nd Yag laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7% lidocaine / 7% tetracaine cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients recieve both the active comparator and the experimental arm. Patients in the acne keloidalis nuchae group will be treated with the Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser and patients in the tattoo removal group with the Q-switched nd Yag laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2,5% lidocaine / 2,5% prilocaine cream</intervention_name>
    <description>The treatment area (either of the acne keloidalis nuchae group or the tattoo group) will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.</description>
    <arm_group_label>2,5% lidocaine / 2,5% prilocaine cream</arm_group_label>
    <other_name>Emla®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7% lidocaine / 7% tetracaine cream</intervention_name>
    <description>The treatment area (either of the acne keloidalis nuchae group or the tattoo group) will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to  the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.</description>
    <arm_group_label>7% lidocaine / 7% tetracaine cream</arm_group_label>
    <other_name>Pliaglis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser</intervention_name>
    <description>Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.</description>
    <arm_group_label>2,5% lidocaine / 2,5% prilocaine cream</arm_group_label>
    <arm_group_label>7% lidocaine / 7% tetracaine cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-switched nd Yag laser</intervention_name>
    <description>Tattoo removal: we will use a 3 mm spotsize and a fluence of 6-10 J/cm2 (depending on the absorption of the laser light, which is visible as skin whitening).</description>
    <arm_group_label>2,5% lidocaine / 2,5% prilocaine cream</arm_group_label>
    <arm_group_label>7% lidocaine / 7% tetracaine cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Subject has provided written informed consent;

               -  Subject is ≥ 18 years of age at time of screening;

               -  Group A: subjects with acne keloidalis nuchae;

               -  Group B: subjects with an uniform, black, professionally placed tattoo

        Exclusion Criteria:

          -  • Known sensitivity to any components of the test materials;

               -  Pregnant or breast-feeding women;

               -  Use of any other pain medication during past 24 hours prior to the laser
                  treatment;

               -  Damaged skin at the designated treatment site;

               -  Blister formation and/or scar formation after test-treatment with standard laser
                  settings;

               -  Any medical or psychiatric condition which, in the investigator's opinion, would
                  preclude the participant from adhering to the protocol or completing the study
                  per protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn van Doorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Greveling</last_name>
    <phone>+31107032063</phone>
    <email>k.greveling@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greveling</last_name>
      <email>k.greveling@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 20, 2015</lastchanged_date>
  <firstreceived_date>February 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.B.A. van Doorn</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>7% lidocaine / 7% tetracaine cream</keyword>
  <keyword>2,5% lidocaine / 2,5% prilocaine cream</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
